NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
NuCana plc - American Depositary Shares (NCNA)
Last nucana plc - american depositary shares earnings: 3/10 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/ncna/historical
Company Research
Source: GlobeNewswire
EDINBURGH, United Kingdom, Dec. 10, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) presented the latest clinical data at the annual European Society for Medical Oncology (“ESMO”) Immuno-Oncology Congress, December 10-12, 2025, in London. The data from patients with PD-1 inhibitor-resistant metastatic melanoma treated with NUC-7738 in combination with pembrolizumab continue to demonstrate clinical activity and a favorable safety profile. All patients had progressive disease prior to starting treatment. Clinical activity includes two partial responses (one confirmed) and seven cases of stable disease, notably including one ongoing stable disease converting to a complete metabolic response with no detectable active disease. These results further reinforce the initial findings presented at the ESMO Congress 2024. As of the most recent analysis, nine patients have been treated in the Expansion Cohort, which is part of the planned enrollment of up to 28
Show less
Read more
Impact Snapshot
Event Time:
NCNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NCNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NCNA alerts
High impacting NuCana plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
NCNA
News
- NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma [Yahoo! Finance]Yahoo! Finance
- NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in ChinaGlobeNewswire
- NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025 [Yahoo! Finance]Yahoo! Finance
- NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025GlobeNewswire
- NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 TherapyGlobeNewswire
NCNA
Sec Filings
- 12/10/25 - Form 6-K
- 11/5/25 - Form 6-K
- 10/20/25 - Form 6-K
- NCNA's page on the SEC website